Opthea Limited (OPT) is a biotechnology company focused on development of new drugs for the treatment of eye diseases.
Opthea's lead asset, OPT - 302, is a soluble form of VEGFR-3 in clinical development as a novel therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Wet AMD and DME are causes of blindness in the elderly and diabetic populations respectively, and are increasing in prevalence worldwide.